Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Finance Watch: Scion Life Sciences Launches With $310m Inaugural VC Fund

Apple Tree Veterans Form New Firm

Executive Summary

Private Company Edition: Scion’s first fund exceeded its initial $250m fundraising goal. Also, The Column Group’s incubator raised a $400m-plus fund and Seroba’s fourth fund reaches $134m, while Neurona raised a $120m financing and Cour closed a $105m series A round.

You may also be interested in...



BMS Makes Second Big Buy Of December, Pays $4.1bn For RayzeBio

Bristol Myers Squibb makes its entrance into the increasingly competitive space of radiopharmaceuticals with its latest purchase, just days after its $14bn Karuna buy.

Takeda Uses AcuraStem Deal To Bolster Neuro Pipeline, Move Into ALS

Deal Snapshot: Looking to add to its neuroscience pipeline, Takeda acquires rights to the antisense candidate AS-202 from AcuraStem for development as a potential amyotrophic lateral sclerosis therapy.

Germany’s Complement Bets On Gene Therapy For Geographic Atrophy

US approval of Apellis's Syfovre has validated the complement approach for treating the advanced stage of age-related macular degeneration but a Munich-headquartered start-up believes its gene therapy will be a more potent and less burdensome alternative.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149769

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel